- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Patent holdings for IPC class A61P 33/02
Total number of patents in this class: 941
10-year publication summary
35
|
45
|
51
|
62
|
68
|
68
|
83
|
69
|
52
|
22
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Novartis AG | 10882 |
20 |
CEVA Sante Animale | 688 |
15 |
Anacor Pharmaceuticals, Inc. | 71 |
11 |
Bayer Animal Health GmbH | 223 |
10 |
Fundacao Oswaldo Cruz | 105 |
10 |
Universidade Federal de Minas Gerais - Ufmg | 193 |
10 |
Universidad de Granada | 307 |
9 |
Centre National de La Recherche Scientifique | 10395 |
8 |
Nihon Nohyaku Co., Ltd. | 325 |
8 |
University of Dundee | 215 |
8 |
Kimberly-clark Worldwide, Inc. | 5502 |
7 |
Glaxosmithkline Intellectual Property Development Limited | 757 |
7 |
The Board of Trustees of the Leland Stanford Junior University | 6394 |
7 |
President and Fellows of Harvard College | 5957 |
7 |
CJ Cheiljedang Corporation | 3401 |
7 |
Consejo Superior de Investigaciones Cientificas (csic) | 1365 |
7 |
Institut de Recherche pour le Developpement (ird) | 149 |
7 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2839 |
7 |
The United States of America, as represented by the Secretary of Agriculture | 1097 |
7 |
Zivo BioScience, Inc. | 51 |
7 |
Other owners | 762 |